EL PASO, Texas, May 8 (UPI) -- Premier Biomedical Inc. has started talks with the U.S. military on conducting clinical trials on molecular compounds resulting from head trauma.
The aim of the trials would be to measure and eliminate specific compounds found in the cerebral-spinal fluids of head trauma victims and which are believed linked to Post-Traumatic Stress Disorder and self-destruction thoughts.
The proposed staged trials Premier Biomedical is discussing with the William Beaumont Army Medical Center at Ft. Bliss, Texas, would build on successful laboratory work the bio-pharmaceutical company and its affiliates conducted earlier.
"The Department of Defense vetted us and our technology for three years before partnering with Premier Biomedical and the University of Texas at El Paso to work together as a team to solve this pressing problem," said William Hartman, president and chief executive officer Premier Biomedical. "The Veterans Administration estimated that one active-duty person per day commits suicide as a result of this problem; counting veterans, this number jumps to almost one suicide per hour, 24 hours per day, 365 days per year!
"We are excited to take this next further step together involving staged clinical trials to bring us that much closer to developing a cure for those who are suffering the effects of head trauma-related incidents. This has huge potential health ramifications for our soldiers and the American public as a whole, particularly those injured during sports participation."
